Clinical Trials

OTTAWA, ONTARIO–(Marketwired – Jan. 16, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its […]

by

OTTAWA, ONTARIO–(Marketwired – Jan. 16, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its […]

by

PHOENIX, Dec. 19, 2017 (GLOBE NEWSWIRE) — Can a synthetic formulation of cannabidiol (CBD), one of the main molecules in cannabis, safely help control treatment-resistant “staring†… read more at: http://markets.businessinsider.com/news/stocks/INSYS-Therapeutics-Initiates-Phase-2-Clinical-Trial-of-Cannabidiol-CBD-Oral-Solution-for-Treatment-of-Refractory-Childhood-Absence-Epilepsy-in-Pediatric-PatientsProof-of-concept-study-aims-to-1011641158

by

PHOENIX, Dec. 19, 2017 (GLOBE NEWSWIRE) — Can a synthetic formulation of cannabidiol (CBD), one of the main molecules in cannabis, safely help control treatment-resistant “staring†… read more at: http://markets.businessinsider.com/news/stocks/INSYS-Therapeutics-Initiates-Phase-2-Clinical-Trial-of-Cannabidiol-CBD-Oral-Solution-for-Treatment-of-Refractory-Childhood-Absence-Epilepsy-in-Pediatric-PatientsProof-of-concept-study-aims-to-1011641158

by

What happened After the company announced its progress in developing drugs derived from marijuana cannabinoids, shares of Insys Therapeutics (NASDAQ:INSY) shot up 81.5% in December, according to SP Global Market Intelligence. So what Insys Therapeutics would probably like a do-over on the first 11 months of 2017, but shares came roaring back in December after management reported […]

by

Shutterstock photo (RTTNews.com) – The following are some of today’s top gainers in the pharma/biotech sector. 1. Arrowhead Pharmaceuticals Inc. (ARWR) Gained 24.73% to close Wednesday’s (Jan.3) trading at $4.64. The stock hit a new intraday high of $4.88. News: No news Pipeline: In 2016, Arrowhead had to discontinue development of prior generation drugs, ARC-520, […]

by

Whenever Zachary Smith posts new content, you’ll get an email delivered to your inbox with a link. Email notifications are only sent once a day, and only if there are new matching items. … read more at: http://muscatinejournal.com/muscatine/news/local/county-attorney-issues-reminder-cannabidiol-is-illegal/article_fe0d4479-5195-58d0-a868-a2c914284b75.html

by

Image : geralt A King’s College London clinical trial involving the cannabis compound CBD has shown it may be beneficial in treating psychosis in schizophrenia. While cannabis can pose a risk to people with schizophrenia, this is thought to be primarily due to the effects tetrahydrocannabinol (THC), the psychoactive component that can induce paranoia, anxiety […]

by

The Top CBD Cannabis Studies of 2017 The past year was important for proponents of medical cannabis. Those seeking to remove cannabis’ Schedule I status are now armed with even more evidence for its medicinal and wellness benefits from a combination of human and rodent studies. From benefits in epilepsy, autism, and beyond, here are […]

by

The Top CBD Cannabis Studies of 2017 The past year was important for proponents of medical cannabis. Those seeking to remove cannabis’ Schedule I status are now armed with even more evidence for its medicinal and wellness benefits from a combination of human and rodent studies. From benefits in epilepsy, autism, and beyond, here are […]

by

(RTTNews) – The following are some of today’s top gainers in the pharma/biotech sector. 1. Agile Therapeutics Inc. (AGRX) Gained 17.06% to close Tuesday’s (Dec.26) trading at $2.95. Looks like the stock is gaining some of what it lost on December 22, 2017. On December 22, 2017, the FDA refused to approve the Company’s investigational […]

by

PHOENIX, Dec. 19, 2017 (GLOBE NEWSWIRE) — Can a synthetic formulation of cannabidiol (CBD), one of the main molecules in cannabis, safely help control treatment-resistant “staring” seizures in children with epilepsy? Working with pediatric patients who suffer from this debilitating condition and their clinicians, INSYS Therapeutics (NASDAQ:INSY) plans to find out by conducting a study […]

by